Jing Renjie, Yao Huayan, Yan Qun, Xue Yanbin, Sun Wen, Lu Ping, Zhang Zizheng, Xie Rui, Cui Bin, Feng Bo
Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the People's Republic of China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Computer Net Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Endocr Pract. 2023 Oct;29(10):747-753. doi: 10.1016/j.eprac.2023.07.001. Epub 2023 Jul 7.
Cardiovascular disease (CVD) is the major cause of death among persons with diabetes. As the preventative use of statin has been proved to reduce CVD risks, understanding the current status and the trend in statin use is crucial to improve clinical treatment strategies.
Our study aimed to answer the question of what were the status and trend of statin use in Shanghai, China.
Our study estimated statin use and trends from 2015 to 2021 among 702 727 patients with type 2 diabetes mellitus (T2DM) based on electronic health records from the Shanghai Hospital Link Database. Patients were grouped according to the presence of CVDs, tested separately for statin primary and secondary prevention use, and stratified by age and sex.
In the study population, 221 127 patients (31.5%) received statin therapy, and among patients with CVD, 157 622 patients (51.62%) received statin therapy for secondary prevention, but only 15% of patients received statins for primary prevention. The trend in the use of statins was still on the rise from 28.3% in 2015. Statin use increased with age (18-39 years, 14.0%; 40-59 years, 26.8%; 60-74 years, 33.35%; and 75 and over, 36.1%), and women (29.7%, n = 93 977) were less likely to receive statin therapy compared to men (32.9%, n = 127 150).
Despite the rise in statin use in T2DM in recent decades, a large proportion of subjects with T2DM did not receive statin therapy.
心血管疾病（CVD）是糖尿病患者的主要死因。由于他汀类药物的预防性使用已被证明可降低心血管疾病风险，了解他汀类药物使用的现状和趋势对于改善临床治疗策略至关重要。
我们的研究旨在回答中国上海他汀类药物使用的现状和趋势如何这一问题。
我们的研究基于上海医院联动数据库的电子健康记录，估计了2015年至2021年期间702727例2型糖尿病（T2DM）患者中他汀类药物的使用情况和趋势。患者根据是否存在心血管疾病进行分组，分别检测他汀类药物的一级预防和二级预防使用情况，并按年龄和性别进行分层。
在研究人群中，221127例患者（31.5%）接受了他汀类药物治疗，在患有心血管疾病的患者中，157622例患者（51.62%）接受了他汀类药物二级预防治疗，但只有15%的患者接受了他汀类药物一级预防治疗。他汀类药物的使用趋势自2015年的28.3%以来仍在上升。他汀类药物的使用随年龄增长而增加（18 - 39岁，14.0%；40 - 59岁，26.8%；60 - 74岁，33.35%；75岁及以上，36.1%），与男性（32.9%，n = 127150）相比，女性（29.7%，n = 93977）接受他汀类药物治疗的可能性较小。
尽管近几十年来2型糖尿病患者中他汀类药物的使用有所增加，但仍有很大比例的2型糖尿病患者未接受他汀类药物治疗。
